Progress of modern imaging modalities in multiple myeloma.
Toshiki TeraoMatsue KoseiPublished in: International journal of hematology (2022)
Multiple myeloma (MM) is an incurable hematological malignancy, but treatment advances made in the last two decades have markedly improved its prognosis. Imaging has played a particularly important role in the management of myeloma. Whole-body low-dose computed tomography (WBLDCT) is replacing conventional skeletal survey by whole-body X-rays. In addition, magnetic resonance imaging (MRI) and positron-emission tomography/computed tomography (PET/CT) have become important imaging modalities not only for MM diagnosis but also for assessment of myeloma cell infiltration, extramedullary disease, treatment efficacy, and prognosis. However, there is room to improve their accuracy and specificity for assessment of treatment response, tumor volume, and residual disease. This review introduces novel diagnostic techniques, such as WBLDCT, MRI, and PET/CT, discusses their contribution to MM care, and lists areas for future research.
Keyphrases
- positron emission tomography
- pet ct
- computed tomography
- multiple myeloma
- magnetic resonance imaging
- contrast enhanced
- high resolution
- low dose
- pet imaging
- healthcare
- single cell
- image quality
- dual energy
- stem cells
- chronic pain
- cross sectional
- magnetic resonance
- mass spectrometry
- pain management
- combination therapy
- current status
- fluorescence imaging
- replacement therapy